Gordon Van Slyke’s mother and sister both passed away of early onset Alzheimer’s when they were in their early 60s. When he decided to…
UPDATE: 3 March 2024, 8:16 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
Update: As of July 6, 2023, the drug has full, traditional FDA approval. Today, the Food and Drug Administration approved Leqembi (generic name lecanemab), a…
Drugmakers Eisai and Biogen took their anti-amyloid Alzheimer’s treatment, lecanemab, to the finish line. By clearing amyloid plaques in the brains of people with…
Lecanemab, Eisai and Biogen’s experimental anti-amyloid Alzheimer’s drug, which recently wrapped its Phase 3 clinical trials, continues to make the news. Some of these…
The United States imposed a blockade against Cuba in 1961, and currently there isn’t much collaboration — or even, much communication — about medical…
The majority of experimental Alzheimer’s drugs are being designed to halt the progression of the disease — a strategy which so far has yielded…
The approval of the controversial anti-amyloid drug Aduhelm last year marked a major milestone for Alzheimer’s research — it became the first new drug…
New data presented at CTAD about an existing agitation drug, brexpiprazole, in trials for patients with Alzheimer’s, bears potential good news when it comes…
About 90 percent of people with Alzheimer’s disease show behavioral symptoms like agitation, irritability, and anger during the course of the disease. If a caregiver…
Much anticipated Phase 3 data for Alzheimer’s drug lecanemab was presented at CTAD in 2022, showing the drug is as safe as the placebo…
Alzheimer’s disease is a progressive disorder without a cure. While there are drugs which treat many of the symptoms — brain fog, cognitive impairment,…
Update 27 January, 2023: In January 2023, lecanemab was granted accelerated approval by the FDA and made available to patients under the brand name…
A class of medications called cholinesterase inhibitors help to turn back the clock on Alzheimer’s disease’s cognitive symptoms. More than a third people over…
This article was written by Being Patient. Corium, the maker of Adlarity®, a transdermal Alzheimer’s dementia treatment, sponsored the article. Scientists have made substantial…
